Clinical standards for the management of adverse effects during treatment for TB

• Autor(a) principal: Autoria-Múltipla ver em Notas
• Data de Publicação: 2023
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
• Texto Completo: https://www.arca.fiocruz.br/handle/icict/59176
• topic: Tuberculose; Efeitos adversos; Gerenciamento; Toxicidade; Drogas; Segurança; Tuberculosis; Adverse efects; Management; Toxicity; Drugs; Safety

AUTORES: FIOCRUZ. IOC - = A. C. C. Carvalho K. P. Singh,1,2 A. C. C. Carvalho,3 R. Centis,4 L. D’Ambrosio,5 G. B. Migliori,4 S. G. Mpagama,6,7 B. C. Nguyen,8 R. E. Aarnoutse,9 A. Aleksa,10 R. van Altena,11 P. K. Bhavani,12 M. S. Bolhuis,13 S. Borisov,14 N. van’t Boveneind-Vrubleuskaya,13,15 J. Bruchfeld,16,17 J. A. Caminero,18,19 I. Carvalho,20 J. G. Cho,21,22,23 L. Davies Forsman,16,17,24 M. Dedicoat,25 K. Dheda,26,27,28 K. Dooley,29 J. Furin,30 J. M. Garc´ıa-Garc´ıa,31 A. Garcia-Prats,32,33 A. C. Hesseling,32 S. K. Heysell,34 Y. Hu,35 H. Y. Kim,21,22,24 S. Manga,36 B. J. Marais,21,37 I. Margineanu,13 AG. M¨artson,38 M. Munoz Torrico,39 H. M. Nataprawira,40 E. Nunes,41,42 C. W. M. Ong,43,4,45 R. Otto-Knapp,46 D. J. Palmero,47 C. A. Peloquin,48 A. Rendon,49 D. Rossato Silva,50 R. Ruslami,51,52 A. M. I. Saktiawati,53,54 P. Santoso,55 H. S. Schaaf,32 B. Seaworth,56 U. S. H. Simonsson,57 R. Singla,58 A. Skrahina,59 I. Solovic,60 S. Srivastava,56,61,62 S. L. Stocker,24,63 M. G. G. Sturkenboom,13 E. M. Svensson,9,64 M. Tadolini,65,66 T. A. Thomas,34 S. Tiberi,67 J. Trubiano,1,68 Z. F. Udwadia,69 A. R. Verhage,70 D. H. Vu,71 O. W. Akkerman,72,73 J. W. C. Alffenaar,21,22 24 J. T. Denholm1,2,74 KPS, ACCC, RC, LDA, GBH, SGM, BCN, OWA, JWCA and JTD comprised the core writing team. OWA, JWCA and JTD were senior authors. 1Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, 2Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia; 3Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil; 4Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy; 5Public Health Consulting Group, Lugano, Switzerland; 6Kilimanjaro Christian Medical University College, Moshi, 7Kibong’oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania; 8Woolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia; 9Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; 10Grodno State Medical University, Grodno, Belarus; 11Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar; 12Indian Council of Medical Research-National Institute for Research in Tuberculosis; 13Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 14Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia; 15Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands; 16Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden; 17Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; 18Department of Pneumology. University General Hospital of Gran Canaria ‘‘Dr Negrin’’, Las Palmas, Spain; 19ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain; 20Paediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal; 21Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia; 22Westmead Hospital, Sydney, NSW, Australia; 23Parramatta Chest Clinic, Parramatta, NSW, Australia; 24School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; 25Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 26Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, 27South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa; 28Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; 29Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 30Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; 31Tuberculosis Research Programme, SEPAR (Sociedad Espanõla de Neumolog´ıa y Cirug´ıa Tora´ cica), Barcelona, Spain; 32Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa; 33Department of Pediatrics, University of Wisconsin, Madison, WI, USA; 34Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA; 35Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China; 36Tuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru; 37Department of Infectious Diseases and Microbiology, The Children’s Hospital at Westmead, Westmead, NSW, Australia; 38Centre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; 39Cl´ınica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, M´exico City, Mexico; 40Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia; 41Department of Pulmonology of Central Hospital of Maputo, Maputo, 42Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique; 43Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 44National University of Singapore Institute for Health Innovation & Technology (iHealthtech), Singapore, 45Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore; 46German Central Committee Against Tuberculosis (DZK), Berlin, Germany; 47Hospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina; 48Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; 49Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumolog´ıa, CIPTIR, Monterrey, Mexico; 50Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 51TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 52Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 53Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 54Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 55Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia; 56 University of Texas Health Science Center at Tyler, Tyler, TX, USA; 57Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; 58Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India; 59Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus; 60National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ruˇzomberok, Vyˇsn´e Ha´gy, Slovakia; 61 Department of Medicine, The University of Texas at Tyler School ofMedicine, TX, USA; 62Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, TX, USA; 63Department of Clinical Pharmacology and Toxicology, St Vincent’s Hospital, Sydney, NSW, Australia; 64Department of Pharmacy, Uppsala University, Uppsala, Sweden; 65Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant’Orsola, Bologna, Italy; 66Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 67Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; 68Department of Infectious Diseases, Austin Hospital, Melbourne, VIC, Australia; 69P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India; 70Department of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 72Department of Pulmonary Diseases and Tuberculosis, Groningen, and 73Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands; 74Victorian Tuberculosis Program, Melbourne Health, VIC, Australia. -------- KPS, ACCC, RC, LDA, GBH, SGM, BCN, OWA, JWCA and JTD comprised the core writing team. OWA, JWCA and JTD were senior authors. 1Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, 2Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia; 3Laborat ´ orio de Inova¸c ˜ oes em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Funda¸ca˜o Oswaldo Cruz, Rio de Janeiro, RJ, Brazil; 4Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy; 5Public Health Consulting Group, Lugano, Switzerland; 6Kilimanjaro Christian Medical University College, Moshi, 7Kibong’oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania; 8Woolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia; 9Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; 10Grodno State Medical University, Grodno, Belarus; 11Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar; 12Indian Council of Medical Research-National Institute for Research in Tuberculosis; 13Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 14Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia; 15Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands; 16Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden; 17Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; 18Department of Pneumology. University General Hospital of Gran Canaria ‘‘Dr Negrin’’, Las Palmas, Spain; 19ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain; 20Paediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal; 21Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia; 22Westmead Hospital, Sydney, NSW, Australia; 23Parramatta Chest Clinic, Parramatta, NSW, Australia; 24School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; 25Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 26Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, 27South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa; 28Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; 29Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 30Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; 31Tuberculosis Research Programme, SEPAR (Sociedad Espa ˜ nola de Neumolog´ıa y Cirug´ıa Tora´ cica), Barcelona, Spain; 32Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa; 33Department of Pediatrics, University of Wisconsin, Madison, WI, USA; 34Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA; 35Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China; 36Tuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru; 37Department of Infectious Diseases and Microbiology, The Children’s Hospital at Westmead, Westmead, NSW, Australia; 38Centre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; 39Cl´ınica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, M´exico City, Mexico; 40Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia; 41Department of Pulmonology of Central Hospital of Maputo, Maputo, 42Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique; 43Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 44National University of Singapore Institute for Health Innovation & Technology (iHealthtech), Singapore, 45Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore; 46German Central Committee Against Tuberculosis (DZK), Berlin, Germany; 47Hospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina; 48Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; 49Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumolog´ıa, CIPTIR, Monterrey, Mexico; 50Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 51TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 52Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 53Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 54Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 55Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia; 56 University of Texas Health Science Center at Tyler, Tyler, TX, USA; 57Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; 58Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India; 59Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus; 60National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ruˇzomberok, Vyˇsn´e Ha´gy, Slovakia; 61 Department of Medicine, The University of Texas at Tyler School ofMedicine, TX, USA; 62Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, TX, USA; 63Department of Clinical Pharmacology and Toxicology, St Vincent’s Hospital, Sydney, NSW, Australia; 64Department of Pharmacy, Uppsala University, Uppsala, Sweden; 65Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant’Orsola, Bologna, Italy; 66Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 67Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; 68Department of Infectious Diseases, Austin Hospital, Melbourne, VIC, Australia; 69P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India; 70Department of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 72Department of Pulmonary Diseases and Tuberculosis, Groningen, and 73Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands; 74Victorian Tuberculosis Program, Melbourne Health, VIC, Australia. Correspondence to: Kasha P Singh, Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. E-mail: kasha.singh@unimelb.